Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Eisai Co Stock News

ESALFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$26.60

0.441.68%

At close: -

$30.96

4.3616.40%

After Hours: Nov 19, 4:11 PM EDT

Eisai Co (ESALF) Forecast

News

Earnings Eisai Co (ESALF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Eisai Co Stock News | OTC:ESALF | Benzinga

Get the latest news on Eisai Co stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Eisai Co performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, January 24, 2025

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
Vandana Singh - Jan 24, 2025, 12:24PM

Thursday, November 14, 2024

CHMP Recommends EU Approval For Eisai's Leqem...
Benzinga Newsdesk - Nov 14, 2024, 11:04AM

Monday, September 16, 2024

Reported Saturday, Merck And Eisai's Phase 3 ...
Benzinga Newsdesk - Sep 16, 2024, 2:36AM

Thursday, August 22, 2024

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
Vandana Singh - Aug 22, 2024, 1:45PM

Friday, July 26, 2024

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Vandana Singh - Jul 26, 2024, 10:21AM
The Committee For Medicinal Products For Huma...
Benzinga Newsdesk - Jul 26, 2024, 7:24AM

Tuesday, July 16, 2024

Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Benzinga Neuro - Jul 15, 2024, 9:36PM

Wednesday, July 03, 2024

Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Vandana Singh - Jul 3, 2024, 12:13PM

Tuesday, June 11, 2024

Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Shivani Kumaresan - Jun 11, 2024, 7:51AM

Friday, March 22, 2024

European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Vandana Singh - Mar 22, 2024, 1:44PM

Friday, December 08, 2023

Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
Vandana Singh - Dec 8, 2023, 8:26AM
Merck, Eisai Announced That Phase 3 LEAP-001 ...
Benzinga Newsdesk - Dec 8, 2023, 6:48AM

Friday, October 13, 2023

Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
Vandana Singh - Oct 13, 2023, 3:10PM

Tuesday, October 10, 2023

LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
Vandana Singh - Oct 10, 2023, 12:35PM

Monday, September 25, 2023

Amazon Invests Up To $4B In ChatGPT Competitor, Hollywood Writers Accept Preliminary Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
Vandana Singh - Sep 25, 2023, 10:58AM
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
Vandana Singh - Sep 25, 2023, 10:41AM

Friday, September 22, 2023

Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Vandana Singh - Sep 22, 2023, 10:21AM
Merck, Eisai's Two Phase 3 Trials Evaluating ...
Benzinga Newsdesk - Sep 22, 2023, 6:49AM

Friday, August 25, 2023

Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
Vandana Singh - Aug 25, 2023, 11:58AM

Thursday, July 20, 2023

Eisai And Biogen Present Latest Analysis Of L...
Benzinga Newsdesk - Jul 20, 2023, 12:51AM

Friday, July 07, 2023

Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
Vandana Singh - Jul 7, 2023, 1:25PM
Biogen And Eisai Granted Traditional Approval...
Benzinga Newsdesk - Jul 7, 2023, 12:42AM

Tuesday, June 13, 2023

Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
Vandana Singh - Jun 13, 2023, 8:30AM

Monday, June 12, 2023

Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
Vandana Singh - Jun 12, 2023, 2:01PM

Thursday, June 08, 2023

Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
Vandana Singh - Jun 8, 2023, 11:27AM
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
Vandana Singh - Jun 8, 2023, 8:34AM

Thursday, May 04, 2023

Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
Vandana Singh - May 4, 2023, 3:06PM

Friday, April 21, 2023

Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
Vandana Singh - Apr 21, 2023, 12:03PM

Monday, April 10, 2023

Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
Vandana Singh - Apr 10, 2023, 7:18AM

Monday, April 03, 2023

National Institute on Aging Aims Building $300M Alzheimer's Research Database
Vandana Singh - Apr 3, 2023, 9:47AM

Friday, March 31, 2023

Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
Vandana Singh - Mar 31, 2023, 7:57AM

Thursday, March 16, 2023

Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
Vandana Singh - Mar 16, 2023, 12:00PM

Tuesday, March 14, 2023

Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Vandana Singh - Mar 14, 2023, 1:34PM

Monday, March 06, 2023

Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
Vandana Singh - Mar 6, 2023, 10:46AM
FDA Accepted Eisai-Biogen's Supplemental Biol...
Benzinga Newsdesk - Mar 6, 2023, 3:45AM

Friday, January 06, 2023

FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
Vandana Singh - Jan 6, 2023, 2:35PM

Thursday, December 22, 2022

Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
Vandana Singh - Dec 22, 2022, 1:59PM

Tuesday, December 20, 2022

Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
Vandana Singh - Dec 20, 2022, 6:43AM

Wednesday, November 30, 2022

Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Vandana Singh - Nov 30, 2022, 1:03PM
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
Vandana Singh - Nov 30, 2022, 9:50AM

Monday, November 28, 2022

Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
Vandana Singh - Nov 28, 2022, 8:54AM

Monday, November 14, 2022

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Vandana Singh - Nov 14, 2022, 1:17PM

Monday, October 10, 2022

Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
Vandana Singh - Oct 10, 2022, 3:14PM

Monday, September 12, 2022

Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
Vandana Singh - Sep 12, 2022, 6:47AM

Thursday, August 25, 2022

Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
Vandana Singh - Aug 25, 2022, 2:45PM

Wednesday, August 03, 2022

Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
Vandana Singh - Aug 3, 2022, 8:53AM

Wednesday, July 06, 2022

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Vandana Singh - Jul 6, 2022, 9:14AM

Tuesday, May 10, 2022

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Vandana Singh - May 10, 2022, 9:23AM
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
Vandana Singh - May 10, 2022, 6:20AM

Tuesday, March 22, 2022

Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
Vandana Singh - Mar 22, 2022, 1:45PM

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved